| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
HAEGTFT targets the glucagon receptor (GCGR), which is a G protein-coupled receptor involved in glucose homeostasis. GLP-1 and its fragments interact with the GLP-1 receptor (GLP-1R), a member of the class B GPCR family, to stimulate insulin secretion in a glucose-dependent manner. By studying HAEGTFT, researchers can explore the molecular interactions between GLP-1 fragments and their receptors.
|
|---|---|
| ln Vitro |
In vitro, HAEGTFT is used to study GLP-1 receptor binding and activation. As the N-terminal 1-7 fragment of GLP-1, it represents the minimal region required for receptor recognition and biological activity. The peptide is employed in receptor binding assays to characterize the interaction between GLP-1 fragments and the GLP-1 receptor, providing insights into the structural determinants of incretin hormone action.
|
| ln Vivo |
In vivo activity data for HAEGTFT are limited, as the peptide is primarily used as a research tool for in vitro binding and structure-activity studies. The full-length GLP-1 peptide, by contrast, is known to stimulate insulin secretion in vivo in a glucose-dependent manner. HAEGTFT serves as a reference compound for understanding the functional contributions of individual GLP-1 residues to receptor binding and activation.
|
| Enzyme Assay |
In vitro receptor binding assays for HAEGTFT involve measuring the peptide's affinity for the GLP-1 receptor (GLP-1R) using radioligand competition binding techniques. The peptide is incubated with membranes expressing GLP-1R and a radiolabeled GLP-1 analog, and the displacement of the radioligand is quantified to determine binding affinity. These cell-free assays help define the minimal structural requirements for GLP-1 receptor recognition.
|
| Cell Assay |
In vitro cellular assays for HAEGTFT are performed using cell lines expressing the GLP-1 receptor, such as pancreatic β-cell lines. Cells are treated with the peptide, and receptor activation is assessed by measuring downstream signaling events, including cAMP accumulation and calcium mobilization. These assays help characterize the peptide's ability to activate GLP-1R and stimulate insulin secretion pathways.
|
| Animal Protocol |
In vivo animal experimental protocols for HAEGTFT are not extensively documented, as the peptide is primarily used for in vitro research applications. For full-length GLP-1, animal studies typically involve administration to rodents followed by measurement of glucose levels and insulin secretion. HAEGTFT may be used as a control or reference compound in such studies to evaluate the contribution of specific N-terminal residues.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of HAEGTFT have not been systematically characterized. As a peptide, it would be expected to have limited oral bioavailability due to degradation in the gastrointestinal tract. The peptide has a molecular weight of 761.78 and molecular formula C33H47N9O12. It appears as a white lyophilized powder and should be stored at -20°C for long-term stability.
|
| Toxicity/Toxicokinetics |
Toxicological data for HAEGTFT are not extensively reported. As a research-use peptide, its safety profile has not been formally evaluated in preclinical toxicology studies. The compound is intended for research purposes only and is not approved for human therapeutic use. Standard laboratory safety precautions should be followed when handling this peptide.
|
| Additional Infomation |
HAEGTFT is a synthetic peptide with CAS number 926018-95-3, molecular formula C33H47N9O12, and molecular weight 761.78. The sequence is His-Ala-Glu-Gly-Thr-Phe-Thr. It is supplied as a white lyophilized powder with purity ≥95% and is soluble in DMSO. The peptide is used in endocrinology and metabolic research to study GLP-1 structure-activity relationships and insulin regulation pathways.
|
| Molecular Formula |
C33H47N9O12
|
|---|---|
| Molecular Weight |
761.779387712479
|
| Exact Mass |
821.355
|
| CAS # |
926018-95-3
|
| PubChem CID |
155977575
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
13
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
22
|
| Heavy Atom Count |
58
|
| Complexity |
1360
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
[C@H](C(=O)N[C@H](C(=O)O)[C@H](O)C)(NC(=O)[C@]([H])([C@H](O)C)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1NC=NC=1)CC1C=CC=CC=1
|
| InChi Key |
IOGUQTQPKUEFLH-FXWHAICVSA-N
|
| InChi Code |
InChI=1S/C33H47N9O12.C2H4O2/c1-16(38-29(49)21(34)12-20-13-35-15-37-20)28(48)39-22(9-10-25(46)47)30(50)36-14-24(45)41-26(17(2)43)32(52)40-23(11-19-7-5-4-6-8-19)31(51)42-27(18(3)44)33(53)54;1-2(3)4/h4-8,13,15-18,21-23,26-27,43-44H,9-12,14,34H2,1-3H3,(H,35,37)(H,36,50)(H,38,49)(H,39,48)(H,40,52)(H,41,45)(H,42,51)(H,46,47)(H,53,54);1H3,(H,3,4)/t16-,17+,18+,21-,22-,23-,26-,27-;/m0./s1
|
| Chemical Name |
acetic acid;(4S)-4-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]propanoyl]amino]-5-[[2-[[(2S,3R)-1-[[(2S)-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-2-oxoethyl]amino]-5-oxopentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3127 mL | 6.5636 mL | 13.1271 mL | |
| 5 mM | 0.2625 mL | 1.3127 mL | 2.6254 mL | |
| 10 mM | 0.1313 mL | 0.6564 mL | 1.3127 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
